Navigation Links
ExonHit Builds A New Organisation
Date:1/16/2008

nd Abbott Laboratories. Mr. Douglas has experience in cardiovascular, oncology and infectious disease diagnostics. He joins the company as Vice President, Corporate Development and will be responsible for defining major strategic development opportunities for ExonHit Therapeutics. Mr. Douglas will also oversee the project organization and will report to ExonHit Therapeutics' President of the Management Board.

Bruno Tocque, ExonHit's President of the Management Board said, "The technical and management skills of our new collaborators, as well as their combined experience in the development of new diagnostics and in the service business will be of significant importance while we progress towards launching our first Alzheimer's disease diagnostic from blood."

On its own resources, ExonHit Therapeutics aims in 2008 at launching new whole-genome micro-arrays for rats and mice; at organizing its infrastructure in order to commercialize its first blood-based diagnostic for Alzheimer's disease; and at partnering its EHT0202 compound for the treatment of neurodegenerative disorders on the basis on the results of a first Phase II study for which the regulatory dossiers have been filed at the end of this year. At the same time, ExonHit expects that its longstanding collaboration with Allergan for the discovery, development and commercialization of drugs for the treatment of neurodegenerative diseases, pain and ophthalmology will result in further progress over the next two years.

The Management Board and the Supervisory Board have decided to set up this new organization to best realize the value of the Company's intellectual property portfolio. The founders expect to then transfer leadership to a new Management Board that will be elected before March 31, 2008 to pursue a new entrepreneurial venture. " We have been working closely with the founders in order to achieve this new organization" states Laurent Condomine, Chairman of the Supervisory Board, he add
'/>"/>

SOURCE ExonHit Therapeutics SA
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. ExonHit and bioMerieux Amend Their Strategic Partnership
2. ExonHit Gets Regulatory Approval to Initiate a Phase 2 Clinical Trial for EHT 0202 in Alzheimers Disease
3. ExonHit Completes a Prototype to Detect Alzheimers Disease From Blood
4. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2014)... -- Pomerantz LLP is investigating claims on behalf of investors ... IPXL).  Such investors are advised to contact Robert ... ext. 237. The investigation concerns whether Impax ... Sections 10(b) and 20(a) of the Securities Exchange Act ... Impax Laboratories, Inc. (the "Company") issued a press release ...
(Date:7/29/2014)... , July 29, 2014 /PRNewswire-iReach/ -- Nanosyn, Inc. ... FORMA Therapeutics, Inc., to provide access to Nanosyn,s ... lead discovery platform for novel small molecule therapeutics. ... the opportunity to work with FORMA Therapeutics to ... and protein homeostasis. FORMA Therapeutics, decision to work ...
(Date:7/29/2014)... July 29, 2014 TransVac Solutions, the ... collection and transport solutions for hospitals, will be exhibiting ... Engineering (ASHE) Annual Conference & Technical Exhibition Aug. 3-6 ... its technology for making hospitals cleaner, reducing infection risk ... the hospital’s life cycle. Staff will be available ...
(Date:7/29/2014)...  Sigma-Aldrich Corporation (NASDAQ: SIAL ) dramatically ... investment in Green Chemistry and donated more than 8,000 ... the Company announced Monday in its new 2013 ... The report comes in a year ... responsible corporate citizen, including recognition for the second consecutive ...
Breaking Biology Technology:SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Impax Laboratories, Inc. - IPXL 2Nanosyn Announces Expanded Partnership With FORMA Therapeutics 2TransVac Presents Cost Saving Technology at ASHE Conference for Keeping Hospitals Cleaner 2Sigma-Aldrich Achieves Record Success in Environmental, Community Initiatives 2Sigma-Aldrich Achieves Record Success in Environmental, Community Initiatives 3
... Alexza,Pharmaceuticals, Inc. (Nasdaq: ALXA ) announced ... present during the 11th Annual BIO CEO & Investor,Conference ... The presentation,will be webcast from the Waldorf-Astoria Hotel ... To access the presentation via the Web, please go ...
... Feb. 3 Genomic Health,Inc. (Nasdaq: GHDX ) ... and year ended December 31, 2008. , ... to $31.2 million,compared with $19.3 million in the fourth quarter ... assay was $30.9 million in the fourth,quarter of 2008, an ...
... Feb. 3 /PRNewswire-FirstCall/ - Victhom Human Bionics Inc., ... has obtained CE Mark approval for its Neurostep(TM) ... system (CLS) used on peripheral nerves. CE Mark ... the Neurostep(TM) in any of the Member States ...
Cached Biology Technology:Alexza's Corporate Presentation to be Webcast at the 11th Annual BIO CEO & Investor Conference 2Alexza's Corporate Presentation to be Webcast at the 11th Annual BIO CEO & Investor Conference 3Genomic Health Announces Fourth Quarter and Year-End 2008 Financial Results and Business Progress, Provides 2009 Financial Guidance 2Genomic Health Announces Fourth Quarter and Year-End 2008 Financial Results and Business Progress, Provides 2009 Financial Guidance 3Genomic Health Announces Fourth Quarter and Year-End 2008 Financial Results and Business Progress, Provides 2009 Financial Guidance 4Genomic Health Announces Fourth Quarter and Year-End 2008 Financial Results and Business Progress, Provides 2009 Financial Guidance 5Genomic Health Announces Fourth Quarter and Year-End 2008 Financial Results and Business Progress, Provides 2009 Financial Guidance 6Genomic Health Announces Fourth Quarter and Year-End 2008 Financial Results and Business Progress, Provides 2009 Financial Guidance 7Genomic Health Announces Fourth Quarter and Year-End 2008 Financial Results and Business Progress, Provides 2009 Financial Guidance 8Genomic Health Announces Fourth Quarter and Year-End 2008 Financial Results and Business Progress, Provides 2009 Financial Guidance 9Victhom Human Bionics Receives CE Mark for the Neurostep(TM) System, the World's First Fully Implantable Closed-Loop Neuromodulation Therapy for Treatment of Foot Drop 2Victhom Human Bionics Receives CE Mark for the Neurostep(TM) System, the World's First Fully Implantable Closed-Loop Neuromodulation Therapy for Treatment of Foot Drop 3
(Date:7/29/2014)... an easier method to create DNAprotein conjugates. The ... diagnosing diseases. , DNA linked to proteins ... can be used in diagnostic techniques, nanotechnology and ... with DNA can be used for purposes ... biological material. The method also provides easier access ...
(Date:7/29/2014)... the University of Kent has shown for the first ... a breakthrough that could have a major impact on ... of Biosciences uncovered the mechanism whereby the physical properties ... actin filaments are ,fine-tuned, to undertake different functions. ... completely stable, providing a framework for the cell, others ...
(Date:7/29/2014)... to go and almost 2500 registered participants, the final ... The event, a joint venture between the Federation of ... for Biochemistry and Molecular Biology (SFBBM), will take place ... the Palais des Congrs in Paris, France. , The ... life sciences in Europe this year. It features more ...
Breaking Biology News(10 mins):New method provides researchers with efficient tool for tagging proteins 2Counting down to FEBS-EMBO 2014 in Paris, France 2
... fattening than others? What about the risks of bariatric ... (ASN) on December 5-7 for answers to these questions ... Nutrition Conference. The 3-day program delivers valuable ... satellite sessions, and networking opportunities. Credentialed media, science writers ...
...   The Bensalem Township Police Department , in conjunction with ... of DNA testing.  This pilot program known as " BodeHITS ... kind in the country for law enforcement. Bensalem ... with over 6,000 DNA profiles consisting of evidence and reference/individual ...
... , Nov. 19, 2013 Nelson Laboratories ( www.nelsonlabs.com ... (#321) during BIOMEDevice in San ... Thor Rollins, biocompatibility specialist. Those interested in a consultation ... http://photos.prnewswire.com/prnh/20120727/LA47745LOGO ) Rollins will also present, ...
Cached Biology News:Advances and Controversies in Clinical Nutrition: Diet, Technology and Practice 290 Minute DNA Results, A First Of Its Kind, Coming To Bensalem 2Nelson Laboratories to Offer Free Biocompatibility Consultations During BIOMEDevice San Jose 2
Mouse monoclonal [HL-37] to HLA DQ1 + HLA DQ3 ( Abpromise for all tested applications)....
SHEEP ANTI BOVINE BETA-LACTOGLOBULIN A...
... Convenient platform for tube handling and reagent dispensing ... tubes - 96 x 0.3ml U-bottom ... - Thermo-Fast® 96 Non-Skirted Plate - ... x 0.5ml Thermo-Tubes Multiple workstations can be securely stacked ...
6B9...
Biology Products: